Nine Grevy's zebras (Equus grevyi) and three Burchell's zebras (Equus burchellii) were immobilized in a standing position a total of 70 times for minor, nonpainful procedures over a 9-yr period. Standing sedation was successfully obtained with a combination of detomidine and butorphanol on 47 occasions (67.1%). Detomidine i.m. (median 0.10 mg/kg; range: 0.07-0.21) was administered by dart, followed 10 min later by butorphanol i.m. (median 0.13 mg/kg; range 0.04-0.24). The dosages were varied depending on the initial demeanor of the animal. On 23 occasions (32.9%), small amounts of etorphine (median 2.5 microg/kg; range 1.1-12.3 microg/kg) plus acepromazine (median 10 microg/kg; range 4.4-50 microg/kg) (as in Large Animal-Immobilon) had to be administered i.m. to gain sufficient sedation. In these latter cases, the animals were either excited or known for their aggressive character. The zebras were sufficiently immobilized for the length of most procedures (<45 min) without supplementation. At the end of the procedure, the animals were given atipamezole (2 mg per 1 mg detomidine used) and naltrexone (0.1 mg/kg) to reverse the sedative effects, irrespective of whether etorphine was used or not. Standing sedation, using the combination of the alpha-2 agonist detomidine and the partial agonist-antagonist opioid butorphanol (in some cases supplemented with etorphine + acepromazine), proved to be a very efficacious and safe method to be used in zebras under zoo conditions for short-lasting, nonpainful procedures.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1638/2010-0093.1 | DOI Listing |
Vet Anaesth Analg
November 2024
Lumbry Park Veterinary Specialists, Alton, Hampshire, UK.
Objective: To determine whether dogs with magnetic resonance imaging (MRI)-determined intracranial space occupying lesions (MRI-iSOLs) or intracranial hypertension (MRI-ICH) had greater sedation scores and quicker onset of recumbency following premedication with intravenous (IV) butorphanol in comparison with dogs which had normal MRI findings.
Study Design: Prospective, observational study.
Animals: A total of 53 dogs presenting for brain MRI were included.
Vet Anaesth Analg
November 2024
Department of Clinical Sciences, College of Veterinary Medicine, Auburn University, Auburn, AL, USA.
Objective: To assess the effect of two different doses of intramuscular atipamezole on head height (HH) in horses after sedation with detomidine.
Study Design: Randomized, blinded, triple crossover study.
Animals: Eight healthy adult horses.
Pediatr Crit Care Med
December 2024
Department of Family and Community Health; School of Nursing, University of Pennsylvania, Philadelphia, PA.
Objectives: To develop and conduct preliminary testing of the Withdrawal Assessment Tool-Alpha 2 Agonist (WAT-A2A) to monitor dexmedetomidine and clonidine withdrawal symptoms in acutely ill children.
Design: Three-phase instrument development study. Phase 1: retrospective chart review of symptoms exhibited by children with documented dexmedetomidine withdrawal; phase 2: WAT-A2A instrument construction based on phase 1 data; and phase 3: prospective testing of the WAT-A2A in children weaning from alpha 2 agonists (A2As).
J Pediatr Nurs
November 2024
University of Nebraska Medical Center, Department of Biostatistics, Omaha, NE, United States of America.
Vet Surg
November 2024
Clinique Equine de Provence, Saint Cannat, France.
Objective: To report a radical surgical technique for perianal melanomas involving the anal margin in standing horses.
Study Design: Observational retrospective study.
Sample Population: Twenty client-owned horses presented for surgical excision of extensive (≥4 cm) perianal melanomas.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!